445 related articles for article (PubMed ID: 31400383)
1. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
2. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
Zhigaltsev IV; Winters G; Srinivasulu M; Crawford J; Wong M; Amankwa L; Waterhouse D; Masin D; Webb M; Harasym N; Heller L; Bally MB; Ciufolini MA; Cullis PR; Maurer N
J Control Release; 2010 Jun; 144(3):332-40. PubMed ID: 20202473
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.
Bowerman CJ; Byrne JD; Chu KS; Schorzman AN; Keeler AW; Sherwood CA; Perry JL; Luft JC; Darr DB; Deal AM; Napier ME; Zamboni WC; Sharpless NE; Perou CM; DeSimone JM
Nano Lett; 2017 Jan; 17(1):242-248. PubMed ID: 27966988
[TBL] [Abstract][Full Text] [Related]
4. Construction and cellular uptake behavior of redox-sensitive docetaxel prodrug-loaded liposomes.
Ren G; Jiang M; Guo W; Sun B; Lian H; Wang Y; He Z
Pharm Dev Technol; 2018 Jan; 23(1):22-32. PubMed ID: 28121230
[TBL] [Abstract][Full Text] [Related]
5. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
6. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
Koning GA; Morselt HW; Velinova MJ; Donga J; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
Biochim Biophys Acta; 1999 Aug; 1420(1-2):153-67. PubMed ID: 10446299
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity.
Wang J; Xue P; Zhou J; Li L; Xu L; Wang Y
Int J Pharm; 2016 May; 505(1-2):352-60. PubMed ID: 27085643
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
9. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting.
Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P
Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization, and pharmacodynamics of thermosensitive liposomes containing docetaxel.
Zhang H; Gong W; Wang ZY; Yuan SJ; Xie XY; Yang YF; Yang Y; Wang SS; Yang DX; Xuan ZX; Mei XG
J Pharm Sci; 2014 Jul; 103(7):2177-2183. PubMed ID: 24846075
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel prodrug liposomes for tumor therapy: characterization, in vitro and in vivo evaluation.
Ren G; Liu D; Guo W; Wang M; Wu C; Guo M; Ai X; Wang Y; He Z
Drug Deliv; 2016 May; 23(4):1272-81. PubMed ID: 26965023
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel prodrug self-assembled nanosystem: Synthesis, formulation and cytotoxicity.
Jing F; Guo Q; Xu W; Qu H; Sui Z
Bioorg Med Chem Lett; 2018 Feb; 28(4):826-830. PubMed ID: 29395972
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles Containing High Loads of Paclitaxel-Silicate Prodrugs: Formulation, Drug Release, and Anticancer Efficacy.
Han J; Michel AR; Lee HS; Kalscheuer S; Wohl A; Hoye TR; McCormick AV; Panyam J; Macosko CW
Mol Pharm; 2015 Dec; 12(12):4329-35. PubMed ID: 26505116
[TBL] [Abstract][Full Text] [Related]
14. Immunotargeting of liposomes containing lipophilic antitumor prodrugs.
Mori A; Kennel SJ; Huang L
Pharm Res; 1993 Apr; 10(4):507-14. PubMed ID: 8483832
[TBL] [Abstract][Full Text] [Related]
15. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.
Hwang HY; Kim IS; Kwon IC; Kim YH
J Control Release; 2008 May; 128(1):23-31. PubMed ID: 18374444
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
Pan D; Schmieder AH; Wang K; Yang X; Senpan A; Cui G; Killgore K; Kim B; Allen JS; Zhang H; Caruthers SD; Shen B; Wickline SA; Lanza GM
Theranostics; 2014; 4(6):565-78. PubMed ID: 24723979
[TBL] [Abstract][Full Text] [Related]
17. Construction and cellular uptake evaluation of redox-responsive docetaxel prodrug self-assembled nanoparticles.
Ren G; Chen P; Tang J; Wang R; Duan S; Wang R; Xie Y; Zhang S
Drug Dev Ind Pharm; 2018 Apr; 44(4):598-607. PubMed ID: 29157014
[TBL] [Abstract][Full Text] [Related]
18. Dynamic core crosslinked camptothecin prodrug micelles with reduction sensitivity and boronic acid-mediated enhanced endocytosis: An intelligent tumor-targeted delivery nanoplatform.
Huang Y; Zhang W; Xu Y; Zhu S; Wu Y; Chen T; Xiao Y; Lu W; Zhang X; Yu J
Int J Pharm; 2020 Apr; 580():119250. PubMed ID: 32209369
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
20. Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer.
Ganta S; Singh A; Rawal Y; Cacaccio J; Patel NR; Kulkarni P; Ferris CF; Amiji MM; Coleman TP
Drug Deliv; 2016; 23(3):968-80. PubMed ID: 24901206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
